keyword
MENU ▼
Read by QxMD icon Read
search

Zaire

keyword
https://www.readbyqxmd.com/read/29627147/determinants-of-antibody-persistence-across-doses-and-continents-after-single-dose-rvsv-zebov-vaccination-for-ebola-virus-disease-an-observational-cohort-study
#1
Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, José F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara Lemaître, Stéphane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist
BACKGROUND: The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2 years in volunteers who received single-dose rVSV-ZEBOV in three previous trials. METHODS: In this observational cohort study, we prospectively followed-up participants from the African and European phase 1 rVSV-ZEBOV trials, who were vaccinated once in 2014-15 with 300 000 (low dose) or 10-50 million (high dose) plaque-forming units (pfu) of rVSV-ZEBOV vaccine to assess ZEBOV glycoprotein (IgG) antibody persistence...
April 4, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29615747/a-critical-domain-of-ebolavirus-envelope-glycoprotein-determines-glycoform-and-infectivity
#2
Haruhiko Fujihira, Katsuaki Usami, Keita Matsuno, Hideyuki Takeuchi, Kaori Denda-Nagai, Jun-Ichi Furukawa, Yasuro Shinohara, Ayato Takada, Yoshihiro Kawaoka, Tatsuro Irimura
Ebolaviruses comprises 5 species that exert varying degrees of mortality/infectivity in humans with Reston ebolaviruses (REBOV) showing the lowest and Zaire ebolaviruses (ZEBOV) showing the highest. However, the molecular basis of this differential mortality/infectivity remains unclear. Here, we report that the structural features of ebolavirus envelope glycoproteins (GPs) and one of their counter receptors, macrophage galactose-type calcium-type lectin (MGL/CD301), play crucial roles in determining viral infectivity...
April 3, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29615039/efficacy-and-safety-of-artemether-lumefantrine-artesunate-amodiaquine-and-dihydroartemisinin-piperaquine-for-the-treatment-of-uncomplicated-plasmodium-falciparum-malaria-in-three-provinces-in-angola-2017
#3
Elizabeth Davlantes, Pedro Rafael Dimbu, Carolina Miguel Ferreira, Maria Florinda Joao, Dilunvuidi Pode, Jacinto Félix, Edgar Sanhangala, Benjamin Nieto Andrade, Samaly Dos Santos Souza, Eldin Talundzic, Venkatachalam Udhayakumar, Chantelle Owens, Eliane Mbounga, Lubbe Wiesner, Eric S Halsey, José Franco Martins, Filomeno Fortes, Mateusz M Plucinski
BACKGROUND: The Angolan government recommends three artemisinin-based combinations for the treatment of uncomplicated Plasmodium falciparum malaria: artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP). Due to the threat of emerging anti-malarial drug resistance, it is important to periodically monitor the efficacy of artemisinin-based combination therapy (ACT). This study evaluated these medications' therapeutic efficacy in Benguela, Lunda Sul, and Zaire Provinces...
April 3, 2018: Malaria Journal
https://www.readbyqxmd.com/read/29533988/development-and-testing-of-a-method-for-validating-chemical-inactivation-of-ebola-virus
#4
Kendra J Alfson, Anthony Griffiths
Complete inactivation of infectious Ebola virus (EBOV) is required before a sample may be removed from a Biosafety Level 4 laboratory. The United States Federal Select Agent Program regulations require that procedures used to demonstrate chemical inactivation must be validated in-house to confirm complete inactivation. The objective of this study was to develop a method for validating chemical inactivation of EBOV and then demonstrate the effectiveness of several commonly-used inactivation methods. Samples containing infectious EBOV ( Zaire ebolavirus ) in different matrices were treated, and the sample was diluted to limit the cytopathic effect of the inactivant...
March 13, 2018: Viruses
https://www.readbyqxmd.com/read/29514907/distinct-immunogenicity-and-efficacy-of-poxvirus-based-vaccine-candidates-against-ebola-virus-expressing-gp-and-vp40-proteins
#5
Adrián Lázaro-Frías, Sergio Gómez-Medina, Lucas Sánchez-Sampedro, Karl Ljungberg, Mart Ustav, Peter Liljeström, César Muñoz-Fontela, Mariano Esteban, Juan García-Arriaza
Zaire and Sudan ebolavirus species cause a severe disease in humans and non-human primates (NHPs) characterized by high mortality rate. There are no licensed therapies or vaccines against Ebola virus disease (EVD), and the recent 2013-2016 outbreak in West Africa highlighted the need of EVD-specific medical countermeasures. Here, we have generated and characterized head-to-head the immunogenicity and efficacy of five vaccine candidates against Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV) based on the highly attenuated poxvirus vector modified vaccinia virus Ankara (MVA), expressing either the virus glycoprotein (GP) or GP together with the virus protein 40 (VP40) forming virus-like particles (VLPs)...
March 7, 2018: Journal of Virology
https://www.readbyqxmd.com/read/29458380/prevalence-of-molecular-markers-of-artemisinin-and-lumefantrine-resistance-among-patients-with-uncomplicated-plasmodium-falciparum-malaria-in-three-provinces-in-angola-2015
#6
Dragan Ljolje, Pedro Rafael Dimbu, Julia Kelley, Ira Goldman, Douglas Nace, Aleixo Macaia, Eric S Halsey, Pascal Ringwald, Filomeno Fortes, Venkatachalam Udhayakumar, Eldin Talundzic, Naomi W Lucchi, Mateusz M Plucinski
BACKGROUND: Artemisinin-based combination therapy is the first-line anti-malarial treatment for uncomplicated Plasmodium falciparum infection in Angola. To date, the prevalence of polymorphisms in the pfk13 gene, associated with artemisinin resistance, and pfmdr1, associated with lumefantrine resistance, have not been systematically studied in Angola. METHODS: DNA was isolated from pretreatment and late treatment failure dried blood spots collected during the 2015 round of therapeutic efficacy studies in Benguela, Lunda Sul, and Zaire Provinces in Angola...
February 20, 2018: Malaria Journal
https://www.readbyqxmd.com/read/29456826/seroprevalence-of-ebola-virus-infection-in-bombali-district-sierra-leone
#7
Nadege Goumkwa Mafopa, Gianluca Russo, Raoul Emeric Guetiya Wadoum, Emmanuel Iwerima, Vincent Batwala, Marta Giovanetti, Antonella Minutolo, Patrick Turay, Thomas B Turay, Brima Kargbo, Massimo Amicosante, Maurizio Mattei, Carla Montesano
A serosurvey of anti-Ebola Zaire virus nucleoprotein IgG prevalence was carried out among Ebola virus disease survivors and their Community Contacts in Bombali District, Sierra Leone. Our data suggest that the specie of Ebola virus ( Zaire ) responsible of the 2013-2016 epidemic in West Africa may cause mild or asymptomatic infection in a proportion of cases, possibly due to an efficient immune response.
December 31, 2017: Journal of Public Health in Africa
https://www.readbyqxmd.com/read/29451827/sending-the-right-message-wild-game-and-the-west-africa-ebola-outbreak
#8
Kristin Post
The unprecedented scale of the Ebola epidemic in West Africa in 2014-15 caught the world by surprise. Zaire Ebolavirus had not previously been documented in Guinea, Sierra Leone, or Liberia. However, since this strain of filovirus was first identified in 1976, scientists have been studying the disease and its origins. They have identified forest-dwelling animals that carry the virus, and some that die from it, but have yet to isolate how it is transmitted from animals to humans. During the height of the Ebola outbreak in West Africa, some public health messages addressed the link among Ebola, wild animals, and humans...
January 2018: Health Security
https://www.readbyqxmd.com/read/29363421/mapping-hla-a2-a3-and-b7-supertype-restricted-t-cell-epitopes-in-the-ebolavirus-proteome
#9
Wan Ching Lim, Asif M Khan
BACKGROUND: Ebolavirus (EBOV) is responsible for one of the most fatal diseases encountered by mankind. Cellular T-cell responses have been implicated to be important in providing protection against the virus. Antigenic variation can result in viral escape from immune recognition. Mapping targets of immune responses among the sequence of viral proteins is, thus, an important first step towards understanding the immune responses to viral variants and can aid in the identification of vaccine targets...
January 19, 2018: BMC Genomics
https://www.readbyqxmd.com/read/29350545/sensitive-multiplex-real-time-rt-qpcr-assay-for-the-detection-of-filoviruses
#10
Vladimir G Dedkov, N'Faly Magassouba, Marina V Safonova, Sergey A Bodnev, Oleg V Pyankov, Jacob Camara, Bakary Sylla, Alexander P Agafonov, Victor V Maleev, German A Shipulin
Filoviruses are important etiological agents of emergent diseases with high mortality rates. Traditionally, filovirus fever diseases have primarily been a burden of African countries; however, global interconnectedness has increased the probability of the worldwide spread of filoviruses. Therefore, national healthcare organizations need tools for managing filovirus risk, including diagnostic kits based on real-time reverse transcription PCR (RT-qPCR), as this is the most suitable method for diagnosing filovirus fever diseases...
January 2018: Health Security
https://www.readbyqxmd.com/read/29333037/curcumin-and-natural-derivatives-inhibit-ebola-viral-proteins-an-in-silico-approach
#11
Shruti Baikerikar
Background: Ebola viral disease is a severe and mostly fatal disease in humans caused by Ebola virus. This virus belongs to family Filoviridae and is a single-stranded negative-sense virus. There is no single treatment for this disease which puts forth the need to identify new therapy to control and treat this fatal condition. Curcumin, one of the bioactives of turmeric, has proven antiviral property. Objective: The current study evaluates the inhibitory activity of curcumin, bisdemethoxycurcumin, demethoxycurcumin, and tetrahydrocurcumin against Zaire Ebola viral proteins (VPs)...
December 2017: Pharmacognosy Research
https://www.readbyqxmd.com/read/29329455/serologic-evidence-of-ebolavirus-infection-in-a-population-with-no-history-of-outbreaks-in-the-democratic-republic-of-the-congo
#12
Sabue Mulangu, Vivian H Alfonso, Nicole A Hoff, Reena H Doshi, Prime Mulembakani, Neville K Kisalu, Emile Okitolonda-Wemakoy, Benoit Ilunga Kebela, Hadar Marcus, Joseph Shiloach, Je-Nie Phue, Linda L Wright, Jean-Jacques Muyembe-Tamfum, Nancy J Sullivan, Anne W Rimoin
Background: Previous studies suggest that cases of Ebola virus disease (EVD) may go unreported because they are asymptomatic or unrecognized, but evidence is limited by study designs and sample size. Methods: A large population-based survey was conducted (n = 3415) to assess animal exposures and behaviors associated with Ebolavirus antibody prevalence in rural Kasai Oriental province of the Democratic Republic of Congo (DRC). Fourteen villages were randomly selected and all healthy individuals ≥1 year of age were eligible...
January 30, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29303554/a-serological-point-of-care-test-for-the-detection-of-igg-antibodies-against-ebola-virus-in-human-survivors
#13
Polina Brangel, Ariel Sobarzo, Claudio Parolo, Benjamin S Miller, Philip D Howes, Sigal Gelkop, Julius J Lutwama, John M Dye, Rachel A McKendry, Leslie Lobel, Molly M Stevens
Ebola virus disease causes widespread and highly fatal epidemics in human populations. Today, there is still great need for point-of-care tests for diagnosis, patient management and surveillance, both during and post outbreaks. We present a point-of-care test comprising an immunochromatographic strip and a smartphone reader, which detects and semiquantifies Ebola-specific antibodies in human survivors. We developed a Sudan virus glycoprotein monoplex platform and validated it using sera from 90 human survivors and 31 local noninfected controls...
January 23, 2018: ACS Nano
https://www.readbyqxmd.com/read/29206076/assessment-of-the-ability-of-v920-recombinant-vesicular-stomatitis-zaire-ebolavirus-vaccine-to-replicate-in-relevant-arthropod-cell-cultures-and-vector-species
#14
Nicholas A Bergren, Megan R Miller, Thomas P Monath, Rebekah C Kading
V920, rVSVΔG-ZEBOV-GP, is a recombinant vesicular stomatitis-Zaire ebolavirus vaccine which has shown an acceptable safety profile and provides a protective immune response against Ebola virus disease (EVD) induced by Zaire ebolavirus in humans. The purpose of this study was to determine whether the V920 vaccine is capable of replicating in arthropod cell cultures of relevant vector species and of replicating in live mosquitoes. While the V920 vaccine replicated well in Vero cells, no replication was observed in Anopheles or Aedes mosquito, Culicoides biting midge, or Lutzomyia sand fly cells, nor in live Culex or Aedes mosquitoes following exposure through intrathoracic inoculation or feeding on a high-titer infectious blood meal...
December 5, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29199040/progress-towards-a-vaccine-against-ebola-to-meet-emergency-medical-countermeasure-needs
#15
Daniel N Wolfe, Amanda G Zarrabian, Gary L Disbrow, Eric M Espeland
The Ebola virus epidemic in West Africa proved to be the largest in the history of filovirus outbreaks, causing the World Health Organization to declare a public health emergency of international concern in August of 2014. In collaboration with domestic and international partners, the Biomedical Advanced Research and Development Authority (BARDA) initiated several vaccine development projects in support of the overall response efforts. The urgency associated with the epidemic triggered the clinical evaluation of lead vaccine candidates starting in late 2014...
November 30, 2017: Vaccine
https://www.readbyqxmd.com/read/29142131/single-dose-trivalent-vesiculovax-vaccine-protects-macaques-from-lethal-ebolavirus-and-marburgvirus-challenge
#16
Demetrius Matassov, Chad E Mire, Theresa Latham, Joan B Geisbert, Rong Xu, Ayuko Ota-Setlik, Krystle N Agans, Dean J Kobs, Morgan Q S Wendling, Amanda Burnaugh, Thomas L Rudge, Carol L Sabourin, Michael A Egan, David K Clarke, Thomas W Geisbert, John H Eldridge
Previous studies demonstrated that a single intramuscular (IM) dose of an attenuated vesicular stomatitis virus vector (Vesiculovax™, rVSV-N4CT1) expressing the glycoprotein (GP) from the Mayinga strain of Zaire ebolavirus (EBOV) protected nonhuman primates (NHP) from lethal challenge with EBOV Kikwit and Makona strains. Here we studied the immunogenicity of an expanded range of attenuated rVSV vectors expressing filovirus GP in mice. Based on data from those studies an optimal attenuated tri-valent rVSV vector formulation was identified which included rVSV vectors expressing EBOV, Sudan ebolavirus (SUDV) or Angola strain of Marburg marburgvirus (MARV) GPs...
November 15, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29140409/ebolavirus-interferon-antagonists-protein-interaction-perspectives-to-combat-pathogenesis
#17
Anupam Banerjee, Abantika Pal, Debnath Pal, Pralay Mitra
Zaire ebolavirus, one of the most pathogenic species of Ebolavirus, is a significant threat to the human community being both highly infectious and lethal. The viral proteins (VPs), specifically VP24 and VP35, antagonize the interferon (IFN) proteins accountable for human immune response. Several efforts have been made to design vaccines and therapeutics drugs. However, the success is not encouraging because of limited knowledge about the binding site information of the VPs. Such limitations stem largely from the highly infectious nature of the virus that requires specialized personnel and biosafety laboratories...
November 13, 2017: Briefings in Functional Genomics
https://www.readbyqxmd.com/read/29123522/transcriptome-analysis-of-circulating-immune-cell-subsets-highlight-the-role-of-monocytes-in-zaire-ebola-virus-makona-pathogenesis
#18
Andrea R Menicucci, Krista Versteeg, Courtney Woolsey, Chad E Mire, Joan B Geisbert, Robert W Cross, Krystle N Agans, Allen Jankeel, Thomas W Geisbert, Ilhem Messaoudi
Existing models of Ebola virus disease (EVD) suggest antigen-presenting cells are initial targets of Zaire ebolavirus (ZEBOV). In vitro studies have shown that ZEBOV infection of monocytes and macrophages results in the production of inflammatory mediators, which may cause lymphocyte apoptosis. However, these findings have not been corroborated by in vivo studies. In this study, we report the first longitudinal analysis of transcriptional changes in purified monocytes, T-cells, and B-cells isolated from cynomolgus macaques following infection with ZEBOV-Makona...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29104771/virus-vectored-ebola-vaccines
#19
I V Dolzhikova, E A Tokarskaya, A S Dzharullaeva, A I Tukhvatulin, D V Shcheblyakov, O L Voronina, S I Syromyatnikova, S V Borisevich, V B Pantyukhov, V F Babira, L V Kolobukhina, B S Naroditsky, D Y Logunov, A L Gintsburg
The Ebola virus disease (EVD) is one of the most dangerous infections affecting humans and animals. The first EVD outbreaks occurred in 1976 in Sudan and Zaire. Since then, more than 20 outbreaks have occurred; the largest of which (2014-2016) evolved into an epidemic in West Africa and claimed the lives of more than 11,000 people. Although vaccination is the most effective way to prevent epidemics, there was no licensed vaccine for EVD at the beginning of the latest outbreak. The development of the first vaccines for EVD started in 1980 and has come a long technological way, from inactivated to genetically engineered vaccines based on recombinant viral vectors...
July 2017: Acta Naturae
https://www.readbyqxmd.com/read/28985239/safety-and-immunogenicity-of-rvsv%C3%AE-g-zebov-gp-ebola-vaccine-in-adults-and-children-in-lambar%C3%A3-n%C3%A3-gabon-a-phase-i-randomised-trial
#20
RANDOMIZED CONTROLLED TRIAL
Selidji T Agnandji, José F Fernandes, Emmanuel B Bache, Régis M Obiang Mba, Jessica S Brosnahan, Lumeka Kabwende, Paul Pitzinger, Pieter Staarink, Marguerite Massinga-Loembe, Verena Krähling, Nadine Biedenkopf, Sarah Katharina Fehling, Thomas Strecker, David J Clark, Henry M Staines, Jay W Hooper, Peter Silvera, Vasee Moorthy, Marie-Paule Kieny, Akim A Adegnika, Martin P Grobusch, Stephan Becker, Michael Ramharter, Benjamin Mordmüller, Bertrand Lell, Sanjeev Krishna, Peter G Kremsner
BACKGROUND: The rVSVΔG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 × 107 plaque-forming units (PFU) in a trial in Guinea. This study provides further safety and immunogenicity data. METHODS AND FINDINGS: A randomised, open-label phase I trial in Lambaréné, Gabon, studied 5 single intramuscular vaccine doses of 3 × 103, 3 × 104, 3 × 105, 3 × 106, or 2 × 107 PFU in 115 adults and a dose of 2 × 107 PFU in 20 adolescents and 20 children. The primary objective was safety and tolerability 28 days post-injection...
October 2017: PLoS Medicine
keyword
keyword
15409
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"